Cargando…

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia

ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia. It is responsible for the initiation of leukemia but also indispensable for disease maintenance and propagation, although its function in these latter processes is less clear. We therefore investigated the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaindl, U, Morak, M, Portsmouth, C, Mecklenbräuker, A, Kauer, M, Zeginigg, M, Attarbaschi, A, Haas, O A, Panzer-Grümayer, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948158/ https://www.ncbi.nlm.nih.gov/pubmed/24240203 http://dx.doi.org/10.1038/leu.2013.345

Ejemplares similares

The Leukemia-Specific Fusion Gene ETV6/RUNX1 Perturbs Distinct Key Biological Functions Primarily by Gene Repression
por: Fuka, Gerhard, et al.
Publicado: (2011)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia
por: Ellinghaus, E, et al.
Publicado: (2012)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood ETV6::RUNX1+ and High Hyperdiploid Acute Lymphoblastic Leukemia
por: Brandes, Danielle, et al.
Publicado: (2023)

Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation
por: Zauli, Giorgio, et al.
Publicado: (2022)

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
por: Michaelis, M, et al.
Publicado: (2011)

Nutlin‐3a selects for cells harbouring TP 53 mutations
por: Kucab, Jill E., et al.
Publicado: (2016)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Awakening p53 in senescent cells using nutlin-3
por: Schug, Thaddeus T.
Publicado: (2009)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Evidence for a role of RUNX1 as recombinase cofactor for TCRβ rearrangements and pathological deletions in ETV6-RUNX1 ALL
por: Seitz, V., et al.
Publicado: (2020)

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
por: Ludwig, Michael P., et al.
Publicado: (2023)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol
por: Zajkowicz, Artur, et al.
Publicado: (2013)

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
por: Vesely, C, et al.
Publicado: (2017)

Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium
por: Markowski, Dominique N, et al.
Publicado: (2012)

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia
por: Malinowska-Ozdowy, K, et al.
Publicado: (2015)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
por: Aziz, Moammir H., et al.
Publicado: (2011)

Determination of ETV6‐RUNX1 genomic breakpoint by next‐generation sequencing
por: Jin, Yanliang, et al.
Publicado: (2015)

Modeling the process of childhood ETV6-RUNX1 B-cell leukemias
por: Rodríguez-Hernández, Guillermo, et al.
Publicado: (2017)

Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
por: Pechackova, Sona, et al.
Publicado: (2016)

Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein–protein interactions by the MDM2 ligand nutlin‐3
por: Way, Luke, et al.
Publicado: (2016)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
por: Lerma Clavero, Ada, et al.
Publicado: (2023)

The enigmatic role(s) of P2RY8-CRLF2
por: Panzer-Grümayer, Renate, et al.
Publicado: (2017)

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level
por: Psatha, Konstantina, et al.
Publicado: (2023)

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
por: Drakos, E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k6alvumin9tm4tstochddsh35m